BnR Summit 2025

Belt and Road Summit 2025- Deal-making

10 – 16 Sept 2025 | China (Hong Kong)

ProjectUpdated on 28 August 2025

Single Cell Drug Screening AI Platform

Marco Suen

Founder & CEO at Provectus Therapeutics Limited

Hong Kong, China (Hong Kong)

About

To investigate tumor heterogeneity, we have developed a single-cell culture device capable of isolating and individually culturing over 1.4 million single cells for high-throughput drug testing. Leveraging our proprietary AI model, we can accurately identify drug-resistant single cells, enabling further investigation and more precise prediction of treatment efficacy.

This platform accelerate cancer reserach, R&D progress for advanced therapeutics and predictive diagnostics for personalised cancer treatment.

Project Location

  • China (Hong Kong)

Project Format

  • Private Project

ESG (Environmental, Social, and Governance)

  • Yes

Project Stage

  • Feasibility Study Completed

Main Project Sector

  • Technology

Technology

  • Bio-Tech

Total Project Value

  • 2,500,001 to 5,000,000 USD

Investment Capital Required

  • 1,000,001 to 2,500,000 USD

Interested Format of Cooperation

  • Minority Shareholdings
  • Public–private partnership / Concession
  • R&D Cooperation

Preferred Financing Model

  • Equity
  • Open for negotiation

Previous Funding Stage

  • None

Main Service(s) Required

  • Professional Services

Organisation

Provectus Therapeutics Limited

Hong Kong, China (Hong Kong)

Similar opportunities